Certified Registered Nurse Anesthetist Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

John Manuel

Nurse Anesthetist, Certified Registered Lima, OH Certified Registered Nurse Anesthetist

NPI 1912153875 CMS profile 10504524

2793 Shawnee Rd, Lima, OH 45806

Open in the dashboard

General payments

$6,134

385 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Manuel of Lima, OH is reported in the CMS Open Payments database as having received $6,134 across 385 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Anesthetist, Certified Registered profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,318 74
2024 General $2,081 132
2023 General $1,553 96
2022 General $922 64
2021 General $260 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Manuel
  • Nurse Anesthetist, Certified Registered median
  • Middle half of Nurse Anesthetist, Certified Registered
  • National median

In program year 2025, general payments to John Manuel were reported at $1,318. Among 25,681 Nurse Anesthetist, Certified Registered profiles paid that year, the median was $46 and the middle half received between $23 and $106.

Show as a table
Year John Manuel Nurse Anesthetist, Certified Registered median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $260 $34 $17–$77 $132
2022 $922 $35 $19–$82 $149
2023 $1,553 $38 $20–$90 $160
2024 $2,081 $42 $22–$96 $164
2025 $1,318 $46 $23–$106 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $1,590 88 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,528 115 payments
  3. AbbVie, Inc. $798 55 payments
  4. QOL Medical, LLC $676 32 payments
  5. Janssen Biotech, Inc. $453 26 payments
  6. Lucid Diagnostics Inc. $399 29 payments
  7. Merck Sharp & Dohme Corporation $200 13 payments
  8. Organon LLC $114 6 payments
  9. Lilly USA, LLC $98 5 payments
  10. RedHill Biopharma Inc. $69 3 payments
  11. Other $208 13 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,119 384 payments
  2. Education $14 1 payment
Products named General payments · program years 2021–2025
  1. XIFAXAN $1,222 86 payments
  2. ENTYVIO $1,070 68 payments
  3. RINVOQ $486 38 payments
  4. SIMPONI ARIA $453 26 payments
  5. STELARA $453 26 payments
  6. SIMPONI $453 26 payments
  7. Sucraid $390 17 payments
  8. TRULANCE $307 29 payments
  9. EOHILIA $296 11 payments
  10. MAVYRET $296 16 payments
  11. Other $2,239 131 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$66,268

Medicare's payments for the services billed

Medicare patients

651

Average age 73

Services billed

682

385 women, 266 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 47%
Ischemic heart disease 31%
Diabetes 27%
Depression 19%
Chronic kidney disease 18%
Atrial fibrillation 15%
COPD 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $344
$344 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $329
$329 — —
Sucraid
  • QOL Medical, LLC $253
$253 — —
RINVOQ
  • AbbVie, Inc. $145
$145 — —
EOHILIA
  • Takeda Pharmaceuticals U.S.A., Inc. $135
$135 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

385 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Anesthetist, Certified Registered in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record